Company Profile

ABBOTT INDIA LTD.

NSE : ABBOTINDIABSE : 500488ISIN CODE : INE358A01014Industry : Pharmaceuticals & DrugsHouse : Abbott India - MNC
BSE14700.00177.8 (+1.22 % )
PREV CLOSE (Rs.) 14522.20
OPEN PRICE (Rs.) 14559.40
BID PRICE (QTY) 14658.85 (3 )
OFFER PRICE (QTY) 14695.20 (3 )
VOLUME 577
TODAY'S LOW / HIGH (Rs.)14534.20 14700.00
52 WK LOW / HIGH (Rs.)12500 18569
NSE14674.00 142.4 (+0.98 % )
PREV CLOSE(Rs.) 14531.60
OPEN PRICE (Rs.) 14630.00
BID PRICE (QTY) 14674.00 (3 )
OFFER PRICE (QTY) 14674.80 (1 )
VOLUME 3302
TODAY'S LOW / HIGH(Rs.) 14537.65 14675.00
52 WK LOW / HIGH (Rs.)12501.45 18679.75

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 1.71
TTM EPS (Rs.) 305.51
P/E Ratio 47.74
Book Value (Rs.) 1064.69
Face Value (Rs.) 10
MCap (Rs. in Mn) 309891.32
Price/Earning (TTM) 43.83
Price/Sales (TTM) 7.42
Price/Book (MRQ) 13.70
PAT Margin (%) 14.49
ROCE (%) 36.54
Incorporation Year : 1944

Management Info :

Munir Shaikh - Chairman Anil Joseph - Managing Director

Registered Office :

Address : Unit No. 3,Corporate Park,Sion Trombay Road,
Mumbai,
Maharashtra-400071

Phone : 022-50461000/2000/1119/1117/1116/6797 8888

Website : www.abbott.co.in

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
09Feb02-09-2021$ Re-Appointment Of Ms. Anisha Motwani (DIN Re-Appointment Of Ms. Anish
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Board of Directors at its Meeting held today i.e. February 9, 2021 have approved the re-appointment of Ms. Anisha Motwani (DIN: 06943493) as an Independent Director for a further term of 5 (five) years with effect from April 25, 2021, subject to approval of the Shareholders of the Company at the ensuing Annual General Meeting. Additional details required under the Listing Regulations read with SEBI Circular Nos. CIR/CFD/CMD/412015 dated September 9, 2015 and List/Comp/14/2018-19 dated June 20, 2018, are enclosed as Annexure A. We request you to kindly take the same on records.
Pursuant to Regulation 30 of the Securities and Exchange Board..
02Nov11-02-2020$Abbott India informs about board meeting Abbott India informs about b

In terms of Regulation 29 (1) (a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Abbott India has informed that a Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, November 11, 2020, to consider and approve the text of Unaudited Financial Results of the Company for the second quarter and half year ended on September 30, 2020. Further, that in terms of the company’s code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders and in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) (Amendment) Regulations, 2019, the Trading Window of the Company remains closed from Wednesday, September 30, 2020 to Friday, November 13, 2020.

The above information is a part of company’s filings submitted to BSE.

In terms of Regulation 29 (1) (a) of the Securities and Exchang..
22Oct10-22-2020$Abbott India informs about certificate Abbott India informs about c

Abbott India has informed that it has enclosed Certificate dated October 22, 2020 issued by Neena Bhatia, Practicing Company Secretary, pursuant to Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended September 30, 2020.

The above information is a part of company’s filings submitted to BSE.


Abbott India has informed that it has enclosed Certificate date..
03Sep09-03-2020$Abbott gets nod from DCGI for once-a-day formulation ‘Ivabradine’ Abbott gets nod from DCGI fo

Abbott has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. The company plans to launch Ivabradine prolonged release tablets in the Indian market in the coming weeks.

Abbott India is healthcare company that discovers, develops, manufactures and markets innovative products and services.

Abbott has received approval from the Drugs Controller General..
03Sep09-03-2020$Abbott shines on getting nod from DCGI for once-a-day formulation ‘Ivabradine’ Abbott shines on getting nod

Abbott India is currently trading at Rs. 16561.00, up by 171.80 points or 1.05% from its previous closing of Rs. 16389.20 on the BSE.

The scrip opened at Rs. 16400.00 and has touched a high and low of Rs. 16574.80 and Rs. 16318.35 respectively. So far 118 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 18569.00 on 04-May-2020 and a 52 week low of Rs. 9180.05 on 03-Sep-2019.

Last one week high and low of the scrip stood at Rs. 17249.00 and Rs. 16040.50 respectively. The current market cap of the company is Rs. 35056.99 crore.

The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 7.32% and 17.69% respectively.

Abbott has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. The company plans to launch Ivabradine prolonged release tablets in the Indian market in the coming weeks.

Abbott India is healthcare company that discovers, develops, manufactures and markets innovative products and services.

Abbott India is currently trading at Rs. 16561.00, up by 171.80..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit1771.45929.3
Gross Profit 2378.8 8026.9
Operating Profit 2568.38708.3
Net Sales 10953.740931.4
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Piramal Enterprises (BSE)
 1989.90 (3.75%)
M.Cap ( in Cr)
44234.82
Gland Pharma (BSE)
 2410.80 (2.59%)
M.Cap ( in Cr)
39365.24
Hester Biosciences (BSE)
 1778.00 (2.33%)
M.Cap ( in Cr)
1508.48
Glaxosmithkline Phar (BSE)
 1505.85 (2.64%)
M.Cap ( in Cr)
25309.26
Dr. Reddys Lab (BSE)
 4444.55 (0.87%)
M.Cap ( in Cr)
73841.52
Shareholding Pattern More
PROMOTERS 74.99 %
MUTUAL FUNDS/UTI 4 %
NON-INSTITUTION 18.09 %
FI/BANKS/INSURANCE 0.51 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes